Avadel Pharmaceuticals plc (AVDL)
NASDAQ: AVDL · Real-Time Price · USD
9.78
+0.34 (3.60%)
Jun 6, 2025, 3:01 PM - Market open
Avadel Pharmaceuticals Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2015 - 2019 |
|---|---|---|---|---|---|---|---|
Period Ending | Mar '25 Mar 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2015 - 2019 |
| Revenue | 194.45 | 169.12 | 27.96 | - | - | 22.33 | Upgrade
|
| Revenue Growth (YoY) | 252.64% | 504.79% | - | - | - | -62.28% | Upgrade
|
| Cost of Revenue | 19.33 | 15.28 | 0.85 | - | - | 5.74 | Upgrade
|
| Gross Profit | 175.12 | 153.84 | 27.12 | - | - | 16.59 | Upgrade
|
| Selling, General & Admin | 178 | 181.04 | 151.71 | 74.52 | 68.5 | 32.41 | Upgrade
|
| Research & Development | 16.48 | 15.2 | 13.26 | 20.7 | 17.1 | 20.44 | Upgrade
|
| Operating Expenses | 194.48 | 196.24 | 164.97 | 95.22 | 85.6 | 53.25 | Upgrade
|
| Operating Income | -19.37 | -42.4 | -137.85 | -95.22 | -85.6 | -36.66 | Upgrade
|
| Interest Expense | -10.48 | -10.83 | -9.89 | -12.34 | -9.94 | -12.99 | Upgrade
|
| Interest & Investment Income | 1.74 | 2.53 | - | - | 2.44 | 0.41 | Upgrade
|
| Other Non Operating Income (Expenses) | - | - | 1.89 | 1.22 | - | - | Upgrade
|
| EBT Excluding Unusual Items | -28.11 | -50.7 | -145.85 | -106.34 | -93.1 | -49.25 | Upgrade
|
| Merger & Restructuring Charges | - | - | - | -3.35 | 0.05 | 0.04 | Upgrade
|
| Gain (Loss) on Sale of Investments | 1.43 | 1.63 | -1.8 | -1.75 | -0.1 | -0.44 | Upgrade
|
| Gain (Loss) on Sale of Assets | - | - | - | - | - | 45.76 | Upgrade
|
| Legal Settlements | - | - | - | - | - | -0.8 | Upgrade
|
| Other Unusual Items | - | - | -13.13 | - | - | -0.4 | Upgrade
|
| Pretax Income | -26.67 | -49.08 | -160.78 | -111.44 | -93.15 | -5.08 | Upgrade
|
| Income Tax Expense | -0.26 | -0.25 | -0.5 | 26.03 | -15.82 | -12.11 | Upgrade
|
| Earnings From Continuing Operations | -26.41 | -48.83 | -160.28 | -137.46 | -77.33 | 7.03 | Upgrade
|
| Net Income | -26.41 | -48.83 | -160.28 | -137.46 | -77.33 | 7.03 | Upgrade
|
| Net Income to Common | -26.41 | -48.83 | -160.28 | -137.46 | -77.33 | 7.03 | Upgrade
|
| Shares Outstanding (Basic) | 96 | 95 | 80 | 60 | 59 | 53 | Upgrade
|
| Shares Outstanding (Diluted) | 96 | 95 | 80 | 60 | 59 | 55 | Upgrade
|
| Shares Change (YoY) | 10.61% | 18.67% | 33.41% | 2.66% | 6.54% | 46.89% | Upgrade
|
| EPS (Basic) | -0.27 | -0.51 | -2.00 | -2.29 | -1.32 | 0.13 | Upgrade
|
| EPS (Diluted) | -0.27 | -0.51 | -2.00 | -2.29 | -1.32 | 0.13 | Upgrade
|
| Free Cash Flow | -25.44 | -46.91 | -128.51 | -71.02 | -77.34 | -48.83 | Upgrade
|
| Free Cash Flow Per Share | -0.26 | -0.49 | -1.60 | -1.18 | -1.32 | -0.89 | Upgrade
|
| Gross Margin | 90.06% | 90.97% | 96.97% | - | - | 74.29% | Upgrade
|
| Operating Margin | -9.96% | -25.07% | -492.97% | - | - | -164.15% | Upgrade
|
| Profit Margin | -13.58% | -28.88% | -573.17% | - | - | 31.47% | Upgrade
|
| Free Cash Flow Margin | -13.08% | -27.74% | -459.57% | - | - | -218.64% | Upgrade
|
| EBITDA | -16.4 | -39.72 | -136.08 | -93.72 | -84.78 | -34.97 | Upgrade
|
| EBITDA Margin | -8.43% | -23.48% | - | - | - | -156.58% | Upgrade
|
| D&A For EBITDA | 2.97 | 2.68 | 1.77 | 1.49 | 0.82 | 1.69 | Upgrade
|
| EBIT | -19.37 | -42.4 | -137.85 | -95.22 | -85.6 | -36.66 | Upgrade
|
| EBIT Margin | -9.96% | -25.07% | - | - | - | -164.15% | Upgrade
|
| Advertising Expenses | - | - | - | - | - | 0.31 | Upgrade
|
Updated May 7, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.